%PDF-1.4
%
123 0 obj
<>
endobj
120 0 obj
<>
endobj
197 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-10T11:36:01Z
2024-03-29T00:31:52-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T00:31:52-07:00
application/pdf
Heather
2004-215.feb
uuid:a3ba12cd-1dd1-11b2-0a00-b508277d8900
uuid:a3ba12d1-1dd1-11b2-0a00-d30000000000
endstream
endobj
107 0 obj
<>
endobj
109 0 obj
<>
endobj
108 0 obj
<>
endobj
110 0 obj
<>
endobj
68 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 97 0 R/Type/Page>>
endobj
71 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 99 0 R/Type/Page>>
endobj
74 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 101 0 R/Type/Page>>
endobj
207 0 obj
[211 0 R]
endobj
208 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
8 0 0 8 71.468 737.0293 Tm
(1999;29:973-85.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(23.)-625.1 (David-Ameline J, Lim )54.8 (A, Davodeau F)79.7 (, et al. Selection of )17.7 (T)91.9 (-cells)]TJ
1.875 -1.25 Td
(reactive against autologous B lymphoblastoid cells during chronic)Tj
0 -1.25 TD
(rheumatoid arthritis. J Immunol 1996;157:4697-706.)Tj
-1.875 -1.25 Td
[(24.)-625.1 (Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus )]TJ
1.875 -1.25 Td
(lymphoproliferation after bone marrow transplantation. Blood)Tj
0 Tc 0 Tw T*
(1988;72:520-9.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(25.)-625.1 (Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor)]TJ
1.875 -1.25 Td
(leukocytes to treat Epstein-Barr virus-associated )Tj
T*
(lymphoproliferative disorders after allogeneic bone marrow )Tj
T*
[(transplantation. N Engl J Med 1994;330:1)36.8 (185-91.)]TJ
-1.875 -1.25 Td
[(26.)-625.1 (Murray RJ, Kurilla MG, Brooks JM, et al. Identification of tar)17.7 (get)]TJ
1.875 -1.25 Td
[(antigens for the human cytotoxic )17.7 (T)91.9 (-cell response to Epstein-Barr)]TJ
T*
[(virus \(EBV\): implications for the immune control of EBV)91.7 (-positive)]TJ
T*
(malignancies. J Exp Med 1992;176:157-68.)Tj
-1.875 -1.25 Td
[(27.)-625.1 (Khanna R, Burrows SR, Kurilla MG, et al. Localization of )]TJ
1.875 -1.25 Td
[(Epstein-Barr virus cytotoxic )17.7 (T)91.9 (-cell epitopes using recombinant )]TJ
T*
(vaccinia: implications for vaccine development. J Exp Med)Tj
0 Tc 0 Tw T*
(1992;176:169-76.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(28.)-625.1 (Steven NM, )54.8 (Annels NE, Kumar )54.8 (A, Leese )54.8 (AM, Kurilla MG,)]TJ
1.875 -1.25 Td
[(Rickinson )54.8 (AB. Immediate early and early lytic cycle proteins are)]TJ
T*
[(frequent tar)17.7 (gets of the Epstein-Barr virus-induced cytotoxic )17.7 (T)91.9 (-cell)]TJ
0 Tc T*
(response. J Exp Med 1997;185:1605-17.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(29.)-625.1 (Callan MF)79.7 (, )17.7 (T)69.9 (an L, )54.8 (Annels N, et al. Direct visualization of )]TJ
1.875 -1.25 Td
[(antigen-specific CD8+ )17.7 (T)91.9 (-cells during the primary immune response)]TJ
T*
(to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-402.)Tj
-1.875 -1.25 Td
[(30.)-625.1 (T)69.9 (an LC, Gudgeon N, )54.8 (Annels NE, et al. )54.8 (A)-220.1 (re-evaluation of the )]TJ
1.875 -1.25 Td
[(frequency of CD8+ )17.7 (T)91.9 (-cells specific for EBV)-257.3 (in healthy virus )]TJ
T*
(carriers. J Immunol 1999;162:1827-35.)Tj
-1.875 -1.25 Td
[(31.)-625.1 (Scotet E, David-Ameline J, Peyrat MA, et al. )17.7 (T)91.9 (-cell response to)]TJ
1.875 -1.25 Td
(Epstein-Barr virus transactivators in chronic rheumatoid arthritis. )Tj
0 Tc T*
(J Exp Med 1996;184:1791-800.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(32.)-625.1 (T)69.9 (an LC, Mowat )54.8 (AG, Fazou C, et al. Specificity of )17.7 (T)91.9 (-cells in )]TJ
1.875 -1.25 Td
[(synovial fluid: high frequencies of CD8\(+\) )17.7 (T)91.9 (-cells that are specific)]TJ
T*
[(for certain viral epitopes. )54.8 (Arthritis Res 2000;2:154-64.)]TJ
-1.875 -1.25 Td
[(33.)-625.1 (Gaston JS, Rickinson )54.8 (AB, Epstein MA. Epstein-Barr virus-specific)]TJ
1.875 -1.25 Td
[(cytotoxic )17.7 (T)91.9 (-cell responses in rheumatoid arthritis patients.)]TJ
T*
(Rheumatol Int 1982;2:155-9.)Tj
-1.875 -1.25 Td
[(34.)-625.1 (Fawcett MC, )17.7 (W)79.9 (alker DJ, Grif)17.7 (fiths ID. Demonstration of impaired )]TJ
1.875 -1.25 Td
[(T)91.9 (-cell regulation of Epstein Barr virus stimulated B lymphocytes in)]TJ
T*
[(rheumatoid arthritis with HLA)-220.2 (identical, disease discordant sibling)]TJ
0 Tc T*
[(pairs. )54.9 (Ann Rheum Dis 1988;47:372-6.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(35.)-625.1 (T)69.9 (akei M, Ishiwata )17.7 (T)74 (, Mitamura K, et al. Decreased expression of)]TJ
1.875 -1.25 Td
(signaling lymphocytic-activation molecule-associated protein \(SAP\))Tj
T*
[(transcripts in )17.7 (T)91.8 (-cells from patients with rheumatoid arthritis. Int)]TJ
T*
(Immunol 2001;13:559-65.)Tj
-1.875 -1.25 Td
[(36.)-625.1 (Romagnoli P)110.7 (, Strahan D, Pelosi M, Cantagrel )54.8 (A, van Meerwijk JP)110.7 (. )54.8 (A)]TJ
1.875 -1.25 Td
(potential role for protein tyrosine kinase p56\(lck\) in rheumatoid)Tj
T*
[(arthritis synovial fluid )17.7 (T)-257.1 (lymphocyte hyporesponsiveness. Int)]TJ
T*
(Immunol 2001;13:305-12.)Tj
-1.875 -1.25 Td
[(37.)-625.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.875 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum)-275.1 (1988;31:315-24.)]TJ
-1.875 -1.25 Td
[(38.)-625.1 (Kurz B, Steiert I, Heuchert G, M\237ller CA. New high resolution )]TJ
1.875 -1.25 Td
[(typing strategy for HLA-A)-220.2 (locus alleles based on dye terminator)]TJ
T*
(sequencing of haplotypic group-specific PCR-amplicons of exon 2)Tj
T*
[(and exon 3. )17.7 (T)35 (issue )54.8 (Antigens 1999;53:81-96.)]TJ
-1.875 -1.25 Td
[(39.)-625.1 (Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential)]TJ
1.875 -1.25 Td
(HLA-A2 binding peptides based on independent binding of )Tj
T*
[(individual peptide side-chains. J Immunol)-275.1 (1994;152:163-75.)]TJ
-1.875 -1.25 Td
[(40.)-625.1 (Y)99.8 (ang J, Lemas )17.7 (VM, Flinn IW)91.7 (, Krone C, )54.8 (Ambinder RF)79.7 (. )54.8 (Application)]TJ
1.875 -1.25 Td
[(of the ELISPOT)-257.3 (assay to the characterization of CD8\(+\) responses)]TJ
T*
(to Epstein-Barr virus antigens)Tj
/T1_1 1 Tf
0 Tc 0 Tw [-0.2 (. )]TJ
/T1_0 1 Tf
0.02499 Tw 12.568 0 Td
(Blood 2000;95:241-8.)Tj
-0.00011 Tc -14.443 -1.25 Td
[(41.)-625.1 (Altman JD, Moss P)91.7 (A, Goulder PJ, et al. Phenotypic analysis of )]TJ
0.00729 Tw 1.875 -1.25 Td
[(antigen-specific T)-257.1 (lymphocytes. )-17.7 (Science)-275.1 (1996;274:94-6.)]TJ
0.02499 Tw 31.125 80 Td
[(42.)-625.1 (Ouyang Q, )17.7 (W)79.9 (agner )17.7 (W)91.8 (,)-0.1 ( )17.7 (W)79.9 (alter S, et al. )54.8 (Age-related increase in CD8+)]TJ
1.875 -1.25 Td
[(T)91.9 (-cells carrying receptors for an immunodominant EBV)-257.3 (epitope, but)]TJ
T*
[(decrease in their antigen-specific responsiveness. Mech )54.8 (Ageing Dev)]TJ
0 Tc 0 Tw T*
(2003;124:477-85.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(43.)-625.1 (Kerr BM, Kienzle N, Burrows JM, et al. Identification of type )]TJ
1.875 -1.25 Td
[(B-specific and cross-reactive cytotoxic )17.7 (T)91.9 (-lymphocyte responses to)]TJ
T*
(Epstein-Barr virus)Tj
/T1_1 1 Tf
0 Tc 0 Tw [0.2 (. )]TJ
/T1_0 1 Tf
0.0072 Tw 7.9079 0 Td
[(J V)59.9 (irol)-275 (1996;70:8858-64.)]TJ
-0.00011 Tc 0.02499 Tw -9.7829 -1.25 Td
[(44.)-625.1 (Lee SP)110.7 (, )17.7 (Thomas )17.7 (W)110.9 (A, Murray RJ, et al. HLA)-165.2 (A2.1-restricted )]TJ
1.875 -1.25 Td
[(cytotoxic )17.7 (T)91.9 (-cells recognizing a range of Epstein-Barr virus isolates)]TJ
T*
[(through a defined epitope in latent membrane protein LMP2. J )17.7 (V)59.8 (irol)]TJ
0 Tc 0 Tw T*
(1993;67:7428-35.)Tj
-0.00011 Tc 0.00729 Tw -1.875 -1.25 Td
[(45.)-625.1 (Lee )-17.7 (SP)110.7 (, T)35 (ierney )-17.7 (RJ, Thomas W)110.9 (A, )-17.8 (Brooks )-17.8 (JM, )-17.8 (Rickinson )37.1 (AB.)]TJ
0.02499 Tw 1.875 -1.25 Td
[(Conserved cytotoxic )17.7 (T)-257.1 (lymphocyte \(CTL\) epitopes within )]TJ
T*
(Epstein-Barr virus \(EBV\) latent membrane protein 2, a potential )Tj
T*
[(tar)17.7 (get for CTL-based tumor therapy)64.8 (. J Immunol 1997;158:3325-34.)]TJ
-1.875 -1.25 Td
[(46.)-625.1 (Burrows SR, Sculley )17.7 (TB, Misko IS, Schmidt C, Moss DJ. )54.8 (An)]TJ
1.875 -1.25 Td
[(Epstein-Barr virus-specific cytotoxic )17.7 (T)91.9 (-cell epitope in EBNA3. )]TJ
0 Tc T*
(J Exp Med 1990;171:345-50.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(47.)-625.1 (Burrows SR, Gardner J, Khanna R, et al. Five new cytotoxic )17.7 (T)91.9 (-cell)]TJ
1.875 -1.25 Td
(epitopes identified within Epstein-Barr virus nuclear antigen 3)Tj
/T1_1 1 Tf
0 Tc 0 Tw 25.1379 0 Td
(. )Tj
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw -25.1379 -1.25 Td
[(J Gen )17.7 (V)59.8 (irol 1994;75:2489-93.)]TJ
-1.875 -1.25 Td
[(48.)-625.1 (Azuma M, Philips JH, Lanier LL. CD28-lymphocytes )17.7 (T)-257.1 (antigenic)]TJ
1.875 -1.25 Td
(and functional properties)Tj
/T1_1 1 Tf
0 Tc 0 Tw [-0.3 (. )]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 10.5706 0 Td
[(J Immunol 1993;150:1)36.8 (147-59.)]TJ
-12.4456 -1.25 Td
[(49.)-625.1 (Sallusto F)79.7 (, Lenig D, Forster R, Lipp M, Lanzavecchia )54.8 (A. )17.7 (T)69.9 (wo )]TJ
1.875 -1.25 Td
[(subsets of memory )17.7 (T)-257.1 (lymphocytes with distinct homing potentials)]TJ
T*
[(and ef)17.7 (fector functions. Nature 1999;401:659-60.)]TJ
-1.875 -1.25 Td
[(50.)-625.1 (Rickinson )54.8 (AB, Callan MF)79.7 (, )54.8 (Annels NE. )17.7 (T)91.9 (-cell memory: lessons from)]TJ
1.875 -1.25 Td
[(Epstein-Barr virus infection in man. Philos )17.7 (T)35 (rans R Soc Lond B)]TJ
T*
(Biol Sci 2000;355:391-400.)Tj
-1.875 -1.25 Td
[(51.)-625.1 (Khan N, Sharif)17.7 (f N, Cobbold M, et al. Cytomegalovirus )]TJ
1.875 -1.25 Td
[(seropositivity drives the CD8T)-257.3 (cell repertoire toward greater )]TJ
T*
(clonality in healthy elderly individuals. J Immunol )Tj
0 Tc 0 Tw T*
(2002;169:1984-92.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(52.)-625.1 (Catalina MD, Sullivan JL, Brody RM, Luzuriaga K. Phenotypic and)]TJ
1.875 -1.25 Td
[(functional heterogeneity of EBV)-257.3 (epitope-specific CD8+ )17.7 (T)91.8 (-cells. )]TJ
T*
(J Immunol 2002;168:4184-91.)Tj
-1.875 -1.25 Td
[(53.)-625.1 (Hamann D, Baars P)91.7 (A, Rep MH, et al. Phenotypic and functional)]TJ
1.875 -1.25 Td
[(separation of memory and ef)17.7 (fector human CD8+ )17.7 (T)91.8 (-cells. J Exp Med)]TJ
0 Tc 0 Tw T*
(1997;186:1407-18.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(54.)-625.1 (Martens PB, Goronzy JJ, Schaid D, )17.7 (W)79.9 (eyand CW)91.7 (. Expansion of)]TJ
1.875 -1.25 Td
[(unusual CD4+ )17.7 (T)-257.1 (cells in severe rheumatoid arthritis. )54.8 (Arthritis)]TJ
0 Tc T*
[(Rheum 1997;40:1)36.9 (106-14.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(55.)-625.1 (W)79.9 (eyand CM, Goronzy JJ. Premature immunosenescence in )]TJ
1.875 -1.25 Td
[(rheumatoid arthritis. J Rheumatol 2002;29:1)36.8 (141-6.)]TJ
-1.875 -1.25 Td
[(56.)-625.1 (Appay )17.7 (V)128.9 (, Dunbar PR, Callan M, et al. Memory CD8+ )17.7 (T)91.9 (-cells vary)]TJ
1.875 -1.25 Td
[(in dif)17.7 (ferentiation phenotype in dif)17.7 (ferent persistent virus infections.)]TJ
T*
(Nature Med 2002;8:379-85.)Tj
-1.875 -1.25 Td
[(57.)-625.1 (Filaci G, Suciu-Foca N. CD8\(+\) )17.7 (T)-257.1 (suppressor cells are back to the)]TJ
1.875 -1.25 Td
[(game: are they players in autoimmunity? )54.8 (Autoimmun Rev)]TJ
0 Tc 0 Tw T*
(2002;1:279-83.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(58.)-625.1 (Pawelec G, Ouyang Q, Colonna-Romana G, Candore G, Lio D,)]TJ
1.875 -1.25 Td
(Caruso C. Is human immunosenescence clinically relevant? Looking)Tj
T*
[(for \322immunological risk phenotypes\323. )17.7 (T)35 (rends Immunol)]TJ
0 Tc 0 Tw T*
(2002;23:330-2.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(59.)-625.1 (Franceschi C, Bonafe M, )17.7 (V)110.8 (alensin S. Human immunosenescence:)]TJ
1.875 -1.25 Td
[(the prevailing of innate immunity)64.8 (, the failing of clonotypic )]TJ
T*
[(immunity)64.9 (, and the filling of immunological space. )17.7 (V)110.8 (accine)]TJ
0 Tc 0 Tw T*
(2000;18:1717-20.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(60.)-625.1 (Ponchel F)79.7 (, Mor)17.7 (gan )54.8 (A)79.8 (W)91.8 (, Bingham SJ, et al. Dysregulated )]TJ
1.875 -1.25 Td
[(lymphocyte proliferation and dif)17.7 (ferentiation in patients with)]TJ
T*
(rheumatoid arthritis. Blood 2002;100:4550-6.)Tj
-1.875 -1.25 Td
[(61.)-625.1 (Baecklund E, Sundstrom C, Ekbom )54.8 (A, et al. L)54.8 (ymphoma subtypes in)]TJ
1.875 -1.25 Td
[(patients with rheumatoid arthritis: increased proportion of dif)17.7 (fuse)]TJ
T*
[(lar)17.7 (ge B cell lymphoma. )54.8 (Arthritis Rheum 2003;48:1543-50.)]TJ
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 545.468 56.4344 Tm
(251)Tj
ET
0 0 0 0 k
53.532 69.5 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.5696 Tm
[(Klatt, et al: T)-257.3 (cells in RA)]TJ
ET
0 0 0 0 k
/GS0 gs
103.387 81.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.387 81.25 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
101 0 obj
<>stream
8;Z\6MfRi3#iu#8OPdV*=mSLBZ'31qc:r#NNu0*DQ:74Vp0UrBp>GJmO8Sl"`chpe
q5l'+iKY/Rhs6%jrA@o@H7bTplJW#+@.H:t#9JA!bWCdZ!'AO*"Aj:^B[r_`\_$EZ
Ktb>)`"6VP#nn\"8#u.ZRb>Rc!cN5fggl$cajeuK3XB&W>+6SS3ci_3"<54ci\cf-
Jio#^qX_U7BfM/^FpkgP"5FCj^"dL:<+7-r(bNLSAV+;4EUoAF$QPDI$kTO%dc!4VYAHFiUD0$)0T0Y9"
l[k@G3""V&U6F4=>C'T8'QK3:.h=UMGf3la/KkI"="rm4YO=QT3kY\bLd``cOdsp"
"j[W6I>*d"(*Pi[U17ut*>6GVi'='MV_W\B=97KT4S?d:G.X49rauu@Td592OCWZLI-DBndOU^!-i-ip.
+)*n.Oocr[G1gobg/Z36X6c?)3/9Q4r\@GNT^.Uukc-t'GMdJ_QQU2M\]>(hQI*RE
S9LD5f&)YQNqGk>d6ZM.=(rSKb<.%mQo='4jC]2R!PBumd8m,^#nat&$OmHmY^Jk)
T;A@tGmu*FMR8+;(cB8f)]rdFN$I92R]p0S]b'e367t'QJGG)ZTBWD\Y[COVc@PTn
@b,,1"IbNcbj$7ROk'2/V%"/ABJ0ES$LX'4mQ
endstream
endobj
105 0 obj
[/Indexed/DeviceRGB 255 104 0 R]
endobj
104 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
132 0 obj
<>
endobj
126 0 obj
<>
endobj
170 0 obj
<>
endobj
202 0 obj
<>
endobj
127 0 obj
<>
endobj
161 0 obj
<>stream
HUiPSY~A1=iՍ
nu#HC4!! K!,!@ Y(@*J4NkPX3ў?SnWιpw}džaB@|/o`x3V'̳ZjG\f\z$U
ي7sCW#F8Y>>~%RL?rM>'\C&H^\!T"+ 4(џjL ,OB9ͧ2~@̗%!dB)Ёi~r
Zqra/
Mplq?[c1 a!aFbX֍8V#5EYcF"wYͬ6jhBgf=qvvnY5>g/ss/wcN/TǥɼJ75[1ρ'MWx8{,8Lshm1?{op(-5M+&OB_CjNY5%7#7/KAv0"JW.-E_pkMRڮ\٢d"nNv`;}#}#_jUC6X8p9
In7$YZ w=HxĥŃ&uURiFgTRTřLu]U68rPHN=Ęn4%T'g>ͼ)/:JcAy5Lx#